May 15 2018
Auris announced its collaboration with NeuWave Medical, a subsidiary of Ethicon, Inc. and part of the Johnson & Johnson Medical Devices Companies this week. The goal is to enable robotically assisted bronchoscopic ablation of lesions in the lung. This cooperative development and commercialization agreement calls for a co-development of integrated systems for robotic control, navigation and application of microwave ablation delivered via bronchoscopes.
Excerpts from the press release: “From the beginning, our vision has been to create a platform capable of enabling advanced diagnosis and therapy for a spectrum of disease, using the least-invasive approach,” said Frederic Moll, M.D., co-founder and CEO of Auris Health."
“For those treating people with suspicious nodules in the lung, the holy grail is to one day be able to detect and treat the disease in a single procedure,” said Kazuhiro Yasufuku, MD, Associate Professor of Surgery at the University of Toronto. “When this option becomes a reality, we may see many patients seek early screening and minimally invasive treatment.”Read the Full Press Release
Complications from bronchoscopy are rare and most often minor, but if they occur, may include breathing difficulty, vocal cord spasm, hoarseness, slight fever, vomiting, dizziness, bronchial spasm, infection, low blood oxygen, bleeding from biopsied site, or an allergic reaction to medications. Only rarely do patients experience other more serious complications (for example, collapsed lung, respiratory failure, heart attack and/or cardiac arrhythmia).
Adverse effects from both Mini-PCNL and Ureteroscopy include pain, urinary tract infection, fever, hematuria (presence of blood in urine), exposure to low levels of radiation, retained or residual stones.
Adverse effects from ureteroscopy may include pain, perforation or injury to the ureter, resulting in extravasation of fluid and urine (urinoma), stricture of the ureter with risk of subsequent obstruction (hydronephrosis needing further repair), rare avulsion of the ureter, urinary blood clots, residual stones.
PCNL access may result in minor and major adverse effects. Minor effects include fever and nephrostomy leak. Major adverse effects may include injuries to pleura, liver, spleen, large vessels with related bleeding, gallbladder, duodenum, jejunum, colon with related cutaneous fistula, fever, pain, ileus, elevated counts.
Major adverse effects related to stone removal may include infection and urosepsis, intravascular fluid overload, extravasation of fluid, and post percutaneous nephrolithotomy bleeding.